

Examiner-Initiated Interview Summary	Application No.	Applicant(s)	
	10/765,299 Examiner Leah Schlientz	LANZA ET AL. Art Unit 1618	

All Participants:

Status of Application: _____

(1) Leah Schlientz.

(3) _____.

(2) Kate Murashige (Applicant's representative).

(4) _____.

Date of Interview: 3 April 2007

Time: _____

Type of Interview:

- Telephonic
 Video Conference
 Personal (Copy given to: Applicant Applicant's representative)

Exhibit Shown or Demonstrated: Yes No

If Yes, provide a brief description:

Part I.

Rejection(s) discussed:

112 1st

Claims discussed:

1

Prior art documents discussed:

N/A


Part II.

SUBSTANCE OF INTERVIEW DESCRIBING THE GENERAL NATURE OF WHAT WAS DISCUSSED:

See Continuation Sheet

Part III.

- It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview directly resulted in the allowance of the application. The examiner will provide a written summary of the substance of the interview in the Notice of Allowability.
 It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview did not result in resolution of all issues. A brief summary by the examiner appears in Part II above.



(Examiner/SPE Signature)

(Applicant/Applicant's Representative Signature – if appropriate)

Continuation of Substance of Interview including description of the general nature of what was discussed: The examiner telephoned Ms. Murashige to discuss amending claim 1 in order to avoid a new matter rejection. It was agreed upon to amend the claim to read spacer is -CH₂CH₂- and/or includes a peptide, pseudopeptide, or a polyalkylene glycol, optionally containing a cleavage site. Support for the amendment can be found in the examples, paragraphs 0033 - 0035, 0040-0041, 0079-80, and original claims 3 and 9.